Item 8.01. Other Events.

On November 9, 2021, Aldeyra Therapeutics, Inc. issued a press release (the "Press Release") to announce the completion of enrollment in the Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution in patients with dry eye disease and the reiteration of the Company's New Drug Application submission guidance. The Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits

Exhibit
No.      Description

  99.1     Aldeyra Therapeutics, Inc. Press Release dated November 9, 2021.

104      Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses